The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA,comprising silicon nanoparticles, at least one amino acid,and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.

An isolated, non-naturally occurring cell-penetrating peptide (CPP) comprising the amino acid sequence:

TABLE-US-00001 [SEQ ID NO: 1] RRSRTARAGRPGRNSSRPSAPR
and sequences which have at least 60% similarity to SEQ ID NO: 1.

An object of the invention is to provide an electroporation method for treating vesicles with exogenous material for insertion of the exogenous material into the vesicles which includes the steps of: a. retaining a suspension of the vesicles and the exogenous material in a treatment volume in a chamber which includes electrodes, wherein the chamber has a geometric factor (cm.sup.−1) defined by the quotient of the electrode gap squared (cm.sup.2) divided by the chamber volume (cm.sup.3), wherein the geometric factor is less than or equal to 0.1 cm.sup.−1, wherein the suspension of the vesicles and the exogenous material is in a medium which is adjusted such that the medium has conductivity in a range spanning 50 microSiemens/cm to 500 microSiemens/cm, wherein the suspension is enclosed in the chamber during treatment, and b. treating the suspension enclosed in the chamber with one or more pulsed electric fields. With the method, the treatment volume of the suspension is scalable, and the time of treatment of the vesicles in the chamber is substantially uniform.

An object of the invention is to provide an electroporation method for treating vesicles with exogenous material for insertion of the exogenous material into the vesicles which includes the steps of: a. retaining a suspension of the vesicles and the exogenous material in a treatment volume in a chamber which includes electrodes, wherein the chamber has a geometric factor (cm.sup.−1) defined by the quotient of the electrode gap squared (cm.sup.2) divided by the chamber volume (cm.sup.3), wherein the geometric factor is less than or equal to 0.1 cm.sup.−1, wherein the suspension of the vesicles and the exogenous material is in a medium which is adjusted such that the medium has conductivity in a range spanning 50 microSiemens/cm to 500 microSiemens/cm, wherein the suspension is enclosed in the chamber during treatment, and b. treating the suspension enclosed in the chamber with one or more pulsed electric fields. With the method, the treatment volume of the suspension is scalable, and the time of treatment of the vesicles in the chamber is substantially uniform.

The disclosure relates to novel saponins comprising acetyl residues on two of their sugar residues. These saponins are able to enhance the transfection efficiency to a high extent and show much less cytotoxic side effects than already known saponins.

The disclosure relates to novel saponins comprising acetyl residues on two of their sugar residues. These saponins are able to enhance the transfection efficiency to a high extent and show much less cytotoxic side effects than already known saponins.

A pH-switchable carrier composition includes a plurality of bioactive glass particles, wherein each of the bioactive glass particle is optionally at least a partially coated with a surface modifier; wherein the bioactive glass particles, with or without, the surface modifier can bind to a nucleic acid compound upon contact at pH in the range of about 7 to about 11, and exhibit controlled release of the nucleic acid compound at pH in the range of about 5 to 6.

A pH-switchable carrier composition includes a plurality of bioactive glass particles, wherein each of the bioactive glass particle is optionally at least a partially coated with a surface modifier; wherein the bioactive glass particles, with or without, the surface modifier can bind to a nucleic acid compound upon contact at pH in the range of about 7 to about 11, and exhibit controlled release of the nucleic acid compound at pH in the range of about 5 to 6.